---
layout: default
title: Sacituzumab Govitecan
description: "Sacituzumab Govitecan çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 4 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 152
evidence_level: L5
indication_count: 4
---

# Sacituzumab Govitecan

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>4</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Sacituzumab Govitecanï¼šå¾ä¸‰é™°æ€§ä¹³ç™Œåˆ°æ–°é©æ‡‰ç—‡æ¢ç´¢

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Sacituzumab Govitecan å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Sacituzumab govitecan åŸæœ¬ç”¨æ–¼æ²»ç™‚æ™šæœŸä¸‰é™°æ€§ä¹³ç™ŒåŠ HR+/HER2- ä¹³ç™Œã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**è—¥ç‰©èª˜ç™¼æ€§éª¨è³ªç–é¬†ç—‡ (drug-induced osteoporosis)** æœ‰æ•ˆï¼Œä½†ç›®å‰åƒ…æœ‰æ¨¡å‹é æ¸¬æ”¯æŒï¼Œç¼ºä¹è‡¨åºŠè­‰æ“šã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ™šæœŸä¸‰é™°æ€§ä¹³ç™Œã€HR+/HER2- ä¹³ç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | è—¥ç‰©èª˜ç™¼æ€§éª¨è³ªç–é¬†ç—‡ (drug-induced osteoporosis) |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.78% |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 3 å¼µ |
| å»ºè­°æ±ºç­– | Hold |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. drug-induced osteoporosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.78%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Sacituzumab govitecan æ˜¯ä¸€ç¨®æŠ—é«”è—¥ç‰©è¤‡åˆé«”ï¼ˆADCï¼‰ï¼Œç”±æŠ— Trop-2 æŠ—é«”èˆ‡ SN-38ï¼ˆirinotecan çš„æ´»æ€§ä»£è¬ç‰©ï¼‰é€£çµï¼š

1. **Trop-2 é¶é»**ï¼šTrop-2ï¼ˆtumor-associated calcium signal transducer 2ï¼‰ä¸»è¦åœ¨ä¸Šçš®ç´°èƒè¡¨é”ï¼Œåœ¨å¤šç¨®å¯¦é«”è…«ç˜¤ä¸­éåº¦è¡¨é”ã€‚

2. **ç´°èƒæ¯’æ€§æ©Ÿè½‰**ï¼šSN-38 æ˜¯æ‹“æ’²ç•°æ§‹é…¶ I æŠ‘åˆ¶åŠ‘ï¼Œä¸»è¦ç”¨æ–¼æŠ—è…«ç˜¤æ²»ç™‚ã€‚

3. **é æ¸¬é©æ‡‰ç—‡çš„åˆç†æ€§å­˜ç–‘**ï¼šè—¥ç‰©èª˜ç™¼æ€§éª¨è³ªç–é¬†ç—‡èˆ‡ Trop-2 æˆ–æ‹“æ’²ç•°æ§‹é…¶ I æŠ‘åˆ¶åŠ‘çš„ä½œç”¨æ©Ÿè½‰ç¼ºä¹æ˜ç¢ºé—œè¯ï¼Œæ­¤é æ¸¬çš„ç”Ÿç‰©å­¸åˆç†æ€§è¼ƒä½ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡ Sacituzumab govitecan ç”¨æ–¼è—¥ç‰©èª˜ç™¼æ€§éª¨è³ªç–é¬†ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

ç›®å‰ç„¡ç›¸é—œæ–‡ç»æ”¯æŒã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. severe nonproliferative diabetic retinopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.69%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.69%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. diabetic retinopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.60%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.60%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. diabetic cataract</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.12%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.12%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬001206è™Ÿ | æ‹“é”ç¶­æ³¨å°„åŠ‘ | å‡æ™¶æ³¨å°„åŠ‘ | 1. é©ç”¨æ–¼æ²»ç™‚å…ˆå‰å·²æ¥å—å…©æ¬¡ä»¥ä¸Šå…¨èº«æ€§æ²»ç™‚ç„¡æ•ˆä¹‹ç„¡æ³•åˆ‡é™¤çš„å±€éƒ¨æ™šæœŸæˆ–è½‰ç§»æ€§ä¸‰é™°æ€§ä¹³ç™Œæˆå¹´ç—…äººã€‚2. é©ç”¨æ–¼æ²»ç™‚ HR+/HER2- ä¹³ç™Œï¼Œéå»æ›¾æ¥å—è‡³å°‘2æ¬¡è½‰ç§»æ€§ä¹³ç™Œå…¨èº«æ€§æ²»ç™‚çš„æˆå¹´ç—…äººã€‚ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | æŠ—é«”è—¥ç‰©è¤‡åˆé«” (ADC) |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | é«˜ - ä¸­æ€§ç²’ç´°èƒæ¸›å°‘ç—‡æ˜¯å¸¸è¦‹åš´é‡ä¸è‰¯åæ‡‰ |
| è‡´åæ€§åˆ†ç´š | ä¸­åº¦ |
| ç›£æ¸¬é …ç›® | å®Œæ•´è¡€çƒè¨ˆæ•¸ã€è‚è…åŠŸèƒ½ã€è…¹ç€‰ç—‡ç‹€ |
| è™•ç½®é˜²è­· | éœ€éµå¾ªç´°èƒæ¯’æ€§è—¥ç‰©è™•ç†æ¨™æº– |

## å®‰å…¨æ€§è€ƒé‡

### é‡å¤§è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | ä¾†æº |
|-------------|---------|------|
| Deferiprone | é‡å¤§ | DDInter |
| Irinotecan | é‡å¤§ | DDInter |
| Leflunomide | é‡å¤§ | DDInter |
| Natalizumab | é‡å¤§ | DDInter |
| Adalimumab | é‡å¤§ | DDInter |
| Infliximab | é‡å¤§ | DDInter |
| Etanercept | é‡å¤§ | DDInter |
| Fingolimod | é‡å¤§ | DDInter |
| Apalutamide | é‡å¤§ | DDInter |

### è—¥ç†å­¸æ¨™é¶

| æ¨™é¶ | åŸºå› åç¨± | èªªæ˜ |
|-----|---------|------|
| TROP-2 (tumor associated calcium signal transducer 2) | TACSTD2 | Sacituzumab govitecan çš„æŠ—é«”éƒ¨åˆ†èˆ‡ TROP-2 çµåˆ |

### é‡è¦è­¦èª

- **åš´é‡ä¸­æ€§ç²’ç´°èƒæ¸›å°‘ç—‡**ï¼šå¯èƒ½å°è‡´ç™¼ç†±æ€§ä¸­æ€§ç²’ç´°èƒæ¸›å°‘ç—‡
- **åš´é‡è…¹ç€‰**ï¼šSN-38 å¯å¼•èµ·åš´é‡è…¹ç€‰
- **éæ•åæ‡‰**ï¼šè¼¸æ³¨ç›¸é—œåæ‡‰
- **UGT1A1 å¤šå‹æ€§**ï¼šUGT1A1*28 åŒå‹åˆå­æ‚£è€…å¯èƒ½æœ‰æ›´é«˜æ¯’æ€§é¢¨éšª


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Hepatic Insufficiency** ğŸŸ¡ Moderate
- The safety of sacituzumab govitecan has not been established in patients with moderate or severe liver dysfunction; it has not been tested in patients with serum bilirubin greater than 1.5 times the upper limit of normal (1.5 x ULN), or AST and ALT g...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- There are no data on the pharmacokinetics of sacituzumab govitecan in patients with moderate renal dysfunction or end-stage renal disease (CrCl up to 30 mL/min); caution is recommended in these patients.

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
1. é æ¸¬é©æ‡‰ç—‡ï¼ˆè—¥ç‰©èª˜ç™¼æ€§éª¨è³ªç–é¬†ç—‡ï¼‰èˆ‡è—¥ç‰©ä½œç”¨æ©Ÿè½‰ç¼ºä¹ç”Ÿç‰©å­¸åˆç†æ€§
2. ç„¡è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šæ”¯æŒ
3. ä½œç‚ºç´°èƒæ¯’æ€§è—¥ç‰©ï¼Œç”¨æ–¼éæƒ¡æ€§ç–¾ç—…çš„å®‰å…¨æ€§å ªæ…®
4. æˆæœ¬æ•ˆç›Šæ¯”ä¸é©åˆéª¨è³ªç–é¬†ç—‡é©æ‡‰ç—‡

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- ç™¼ç¾ Trop-2 åœ¨éª¨ä»£è¬ä¸­çš„ç›¸é—œä½œç”¨
- åŸºç¤ç ”ç©¶è­‰æ˜æ©Ÿè½‰åˆç†æ€§
- è€ƒæ…®åˆ°æ¯’æ€§ï¼Œæ­¤é©æ‡‰ç—‡ä¸å»ºè­°é€²ä¸€æ­¥æ¢ç´¢


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Titanium Dioxide]({{ "/drugs/titanium_dioxide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Irbesartan]({{ "/drugs/irbesartan/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Verteporfin]({{ "/drugs/verteporfin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Buprenorphine]({{ "/drugs/buprenorphine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Allopurinol]({{ "/drugs/allopurinol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Sacituzumab Govitecanè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/sacituzumab_govitecan/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_sacituzumab_govitecan,
  title = {Sacituzumab Govitecanè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/sacituzumab_govitecan/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
